The Cat Health Company adds AI small-molecule discovery through Ad Atomica deal

The Cat Health Company has partnered with London-based Ad Atomica to expand its feline longevity pipeline with AI-led de novo small-molecule discovery and optimisation. The deal broadens TCHC’s search for new cat therapies without replacing its internal discovery engine, and financial terms were not disclosed.

Why it matters: - The Cat Health Company is expanding beyond internally developed computational approaches. - The partnership adds a path to proprietary new chemical matter when existing molecules are not suitable. - The move could widen the set of cat diseases that can be targeted with new therapies. - TCHC is trying to keep the fastest and most capital-efficient route to clinical validation while adding a new discovery option.

What happened: - The Cat Health Company entered a strategic partnership with London-based Ad Atomica. - The deal adds AI-led de novo small-molecule discovery and optimisation to TCHC’s feline longevity pipeline. - The partnership was announced Sept. 21, 2026. - Financial terms of the partnership were not disclosed.

The details: - TCHC will continue to prioritise internal candidates and existing molecules when those offer the fastest path from biological hypothesis to clinical validation. - Ad Atomica will be used for targets where no suitable existing molecule or approach is available. - Ad Atomica’s platform uses a closed-loop system that combines computational molecular design, experimental validation and iterative optimisation. - The platform designs molecules, synthesises them, tests them and feeds results back into the system for the next design cycle. - The approach builds molecules atom by atom instead of relying only on existing molecular templates. - The platform is designed to explore novel chemical space while optimising drug-likeness, ADMET properties, target affinity and selectivity. - Ad Atomica’s computational system is connected to experimental capabilities across multiple robotics-enabled laboratories. - TCHC said PURR-001, its first clinical-stage therapeutic, moved from programme start to a European manufacturing and distribution agreement in less than two years.

Between the lines: - TCHC is signaling that speed matters, but so does access to entirely new chemistry. - The partnership suggests the company sees internal discovery and external AI-driven discovery as complementary, not competing, tracks. - Ad Atomica’s pitch is that cats should benefit from the same drug-design tools that are increasingly used in human medicine. - TCHC’s focus on feline health gives the partnership a narrower species-specific application, but also a clearer path to clinical relevance.

What’s next: - TCHC and Ad Atomica plan to identify novel, best-in-class drugs and move them into feline patients when it is safe to do so. - The partnership will likely be used to advance targets that cannot be addressed quickly with existing molecules. - TCHC will continue progressing internal candidates alongside the new AI-led discovery track.

The bottom line: - The Cat Health Company is adding a new AI drug-discovery lane to broaden its pipeline without slowing its existing development strategy.